Alkem Laboratories reports steady growth in line with expectations
The pharmaceutical company posted a 13.5% revenue rise for FY26, accompanied by a final dividend of ₹10 per share.
— 1 earlier story on Alkem Laboratories Ltd. →What's new
- Alkem posted 13.5% revenue growth and 6% PAT growth for FY26.
- The board recommended a final dividend of ₹10 per share.
- Exceptional items related to real estate and labour provisions were previously disclosed.
Why this matters
The results align with market expectations, confirming a stable performance for the large-cap pharma player. With one-time charges already accounted for in prior quarters, the filing offers no surprises to investors.
What we're watching
- Any shifts in the dividend payout policy in future quarters.
- Updates on the real estate investment portfolio.
- Operational performance in the upcoming Q1 FY27 results.
The full read
Alkem Laboratories closed FY26 with 13.5% revenue growth and a 6% increase in profit after tax. These figures match market expectations, marking a routine end to the fiscal year for the large-cap pharmaceutical firm.
It was a quiet quarter.
The board recommended a final dividend of ₹10 per share, maintaining the company's established payout policy. Exceptional items, such as provisions for labour codes and impairment on real estate investments, were already known to the market from prior disclosures. With no material new information provided in this filing, the results offer little to shift the current investment thesis, and the company also confirmed the re-appointment of an executive director. Investors should view this as a standard reporting cycle.
Questions answered
- How did Alkem perform in FY26?
- The company recorded revenue growth of 13.5% and profit after tax growth of 6% for the fiscal year ended March 2026.
- What dividend did the board declare?
- The board recommended a final dividend of ₹10 per share, which remains consistent with the company's existing payout policy.
- Were there any unexpected financial charges?
- No. Exceptional items, including provisions for labour codes and impairment on real estate investments, were previously disclosed in earlier quarters.
- Did the board announce any leadership changes?
- The board approved the re-appointment of an executive director.
Story so far
All notes on ALKEM →- 28 May 2026 · 1:28 PM IST Alkem Laboratories reports steady growth in line with expectations
- today Alkem Laboratories reports 13.5% revenue growth for FY26